DRKS00021039RecruitingNot Applicable
Translational Research for Persons with Abnormal DNA Damage Response - ADDRess
Pädiatrische Hämatologie und OnkologieMedizinische Hochschule Hannover0 sites200 target enrollmentStarted: April 28, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 200
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 0 Years to 120 Years (—)
- Sex
- All
Inclusion Criteria
- •Diagnosis of a cancer predisposition syndrome with underlying DNA repair defect
- •- or: Related person (relative, partner, close person of an LFS victim)
- •- Existence of a written consent to participate in the study
Exclusion Criteria
- •Lack of consent, inability to consent
Investigators
Similar Trials
Recruiting
Not Applicable
TRANSdiagnostic Research into Emotional Disorders and Cognitive-Behavioral Therapy of the Adaptive MindF32F33F34F38F39F40F41F42F43F45F48Depressive episodeRecurrent depressive disorderPersistent mood [affective] disordersOther mood [affective] disordersUnspecified mood [affective] disorderPhobic anxiety disordersOther anxiety disordersReaction to severe stress, and adjustment disordersSomatoform disordersOther neurotic disordersObsessive-compulsive disorderDRKS00031206Justus-Liebig-Universität Gießen200
Completed
Not Applicable
Research on the treatment needs of patients with dementia with Lewy bodies, their caregivers, and their physiciansDementia with Lewy bodies (DLB)JPRN-UMIN000041844Graduate School of Osaka University700
Active, not recruiting
Phase 1
Tracleer - Therapie bei Patienten mit Downsyndrom und Eisenmengerreaktion: Verträglichkeit und hämodynamische Wirkungen.Ein wesentlicher Faktor in der Pathogenese der PAH scheint eine gestörte Endothelfunktion mit erhöhter Produktion bzw. vermindertem Abbau von Endothelin-1 zu sein. Bosentan (Tracleer©) ist ein oraler, dualer Endothelin-Rezeptor-Antagonist, der zur Behandlung der PAH auch in Österreich zugelassen ist. Patienten mit Eisenmenger-Komplex stellen eine Besonderheit dar, weil es durch Beeinflussung des pulmonalen Gefäßwiderstandes zu unmittelbaren Rückwirkungen auf den Systemkreislauf kommen kann.EUCTR2005-005584-28-ATPediatric Cardiology20
Not yet recruiting
Not Applicable
Measurement of Neural Responses to Deep Brain Stimulation in Patients with Movement DisordersMovement DisorderNeurological - Parkinson's diseaseNeurological - Other neurological disordersACTRN12613000201774ational ICT Australia Ltd5
Active, not recruiting
Phase 1
Dexamethasone for treatment of heavy menstrual bleedingEndometrial glucocorticoid deficiency in Heavy Menstrual BleedingMedDRA version: 14.1 Level: PT Classification code 10027313 Term: Menorrhagia System Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2012-003405-98-GBACCORD University of Edinburgh128